NASDAQ · Finance

Drugs Made In America Acquisition Corp. (DMAA)

At June 30, 2026 it held $20.3K in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 14, 2026.

Price

$10.84

-0.09% on the day · September 25, 2026

52-week range $10.26 to $10.86

Market cap

$263.2M

What Drugs Made In America Acquisition Corp. does

Drugs Made In America Acquisition Corp. is registered with the SEC under industry code SIC 6770 (Blank Checks). Its shares trade on NASDAQ under the ticker DMAA.

Key figures

Fiscal year	Revenue	Operating income	Net income	Diluted EPS	Free cash flow
2025	n/a	-$2.8M	$5.9M	n/a	n/a

Full financial statements: income, balance sheet and cash flow

Next report expected around November 17, 2026.

Estimated from its filing rhythm: 52 weeks after its report of November 18, 2025. Not a date the company has announced. See the report calendar

Latest SEC filings

What Drugs Made In America Acquisition Corp. has filed recently, newest first. Each links to the original document on SEC EDGAR.

September 14, 2026
Form 425 filing 425
September 14, 2026
Material agreement 8-K
August 14, 2026
Quarterly report 10-Q · period to June 30, 2026Net income fell 25% to $1.7M.
August 14, 2026
Passive stake changed SCHEDULE 13G/A
August 14, 2026
Passive stake changed SCHEDULE 13G/A
August 13, 2026
Passive stake changed SCHEDULE 13G/A
August 13, 2026
Passive stake changed SCHEDULE 13G/A
July 20, 2026
Form 425 filing 425
July 20, 2026
Material agreement 8-K
June 26, 2026
Passive stake (5% or more) SCHEDULE 13G

Recent insider filings (Forms 3, 4 and 144): 10, the latest on February 18, 2025. Insider transactions on SEC

Who owns DMAA

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

Holder	Of class	Shares	Filed
Karpus Management, Inc.13G, passive	10.33%	2,507,817	August 14, 2026
Feis Equities LLC13G, passive with 1 related filers	5.08%	1,232,775	June 26, 2026

Latest filings below 5%: First Trust Capital Management L.P. 3.24% (August 14, 2026); Glazer Capital, LLC 4.12% (August 13, 2026).

Largest institutional holders

No Form 13F positions imported for this company yet.

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

We have not read this company's Form 4 filings yet.

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about DMAA

What does Drugs Made In America Acquisition Corp. do?

Drugs Made In America Acquisition Corp. is registered with the SEC under industry code SIC 6770 (Blank Checks). Its shares trade on NASDAQ under the ticker DMAA.

Is Drugs Made In America Acquisition Corp. profitable?

Yes. Over the twelve months to June 30, 2026 it reported net income of $6.1M.

When did Drugs Made In America Acquisition Corp. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 14, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the form 425 filing from September 14, 2026.

Similar companies

IPCX

Inflection Point Acquisition Corp. III

AVNI

Arvana Inc

MTAL

Metals Acquisition Corp. II

HCMA

Hcm III Acquisition Corp.

TACO

Berto Acquisition Corp.

CUB

Lionheart Holdings

Compare DMAA with

Compare DMAA with any company

Follow DMAA

Get an email when Drugs Made In America Acquisition Corp. files with the SEC: results, executive changes, material agreements and annual reports.

Follow DMAA: get an email when it files

Where the numbers come from

Financial figures are the values Drugs Made In America Acquisition Corp. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.